Now that I'm not on mobile, I can fill in more details of the initial post

When I made the comment about Telix "running to stand still" I am referring to the R&D and acquisitions, with many acquisitions made using the share placement facility.

R&D increased to 60% from 80.3m to 128.5m which is implying that the cancer space is very competitive at the moment and Telix is spending heaps to stay ahead of the game.

On top of this were the recent acquisitions such as QSAM Biosciences done via equity (v cash).

So despite the numbers, it was going to sell off on the news.

My exit from Telix a few weeks back was from the following:

• QSAM Biosciences acquisition using equity instead of cash.
• Telix seem to always get sold off each time results get announced.
• Couldn't resist the $11-$12 on offer that time.
• Probably less of a factor but Locametz being a possible contender to Illucix (they both use Ga68) although Novartis has chosen not to bring Locametz to market for some reason. We should also not forget Illucix was developed from the ANMI acquisition back in 26 November 2018